Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C

American Journal of Medicine

Volumn 122, Issue 5, 2009, Pages 479-486

  Ikeda, Kenji ^a,b   Arase, Yasuji ^a,b   Kawamura, Yusuke ^a,b   Yatsuji, Hiromi ^a,b   Sezaki, Hitomi ^a,b   Hosaka, Tetsuya ^a,b   Akuta, Norio ^a,b   Kobayashi, Masahiro ^a,b   Saitoh, Satoshi ^a,b   Suzuki, Fumitaka ^a,b   Suzuki, Yoshiyuki ^a,b   Kumada, Hiromitsu ^a,b  

^a TORANOMON HOSPITAL   (Japan)

^b Okinaka Memorial Institute for Medical Research   (Japan)

Author keywords

Chronic hepatitis C virus; Elderly; Hepatocellular carcinogenesis; Interferon; Survival

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; AGED; ANOREXIA; ARTICLE; ASCITES; BRAIN DISEASE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPENIA; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DRUG WITHDRAWAL; ELDERLY CARE; EPILEPSY; EYE TOXICITY; FEMALE; HEPATITIS C; HUMAN; INTERSTITIAL PNEUMONIA; JAUNDICE; LIVER CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; UNCONSCIOUSNESS; VARICOSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 64349117396     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.09.045     Document Type: Article

References (32)

1. Bruix J., Calvet X., Costa J., et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2 (1989) 1004-1006
2. Colombo M., Kuo G., Choo Q.L., et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 2 (1989) 1006-1008
3. Ikeda K., Saitoh S., Koida I., et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 cases with viral and alcoholic cirrhosis. Hepatology 18 (1993) 47-53
4. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 107 (1999) 2S-9S
5. Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 13 (2007) 2436-2441
6. Davis G.L., Balart L.A., Schiff E.R., et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter, randomized, controlled trial. N Engl J Med 321 (1989) 1501-1506
7. Di Bisceglie A.M., Martin P., Kassianides C., et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 321 (1989) 1506-1510
8. Nishiguchi S., Kuroki T., Nakatani S., et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346 (1995) 1051-1055
9. Mazzella G., Accogli E., Sottili S., et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24 (1996) 141-147
10. Kasahara A., Hayashi N., Mochizuki K., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27 (1998) 1394-1402
11. Niederau C., Lange S., Heintges T., et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28 (1998) 1687-1695
12. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351 (1998) 1535-1539
13. Ikeda K., Saitoh S., Arase Y., et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29 (1999) 1124-1130
14. Tsubota A., Chayama K., Ikeda K., et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19 (1994) 1088-1094
15. Hagiwara H., Hayashi N., Mita E., et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 104 (1993) 877-883
16. Floreani A., Monola E., Carderi I., et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C?. J Am Geriatr Soc 54 (2006) 549-550
17. Davis G.L., Albright J.E., Cook S.F., and Rosenberg D.M. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9 (2003) 331-338
18. Taura N., Hamasaki K., Nakao K., et al. Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: long-term trends in Japan. Oncol Rep 16 (2006) 837-843
19. Yoshizawa H., Tanaka J., and Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 49 (2006) 7-17
20. Alessi N., Freni M.A., Spadara A., et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med 11 (2003) 208-212
21. Koyama R., Arase Y., Ikeda K., et al. Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 49 (2006) 121-126
22. Nudo C.G., Wong P., Hilzenrat N., and Deschenes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 20 (2006) 589-592
23. Kaplan E.L., and Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 53 (1958) 457-481
24. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 248-275
25. SPSS Inc. SPSS for Windows Version 11.0 Manual (2001), SPSS Inc, Chicago, IL
26. Bresci G., Del Corso L., Romanelli A.M., et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc 41 (1993) 857-862
27. Horiike N., Masumoto T., Nakanishi K., et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 10 (1995) 246-249
28. Thabut D., Le Calvez S., Thibault V., et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?. Am J Gastroenterol 101 (2006) 1260-1267
29. Honda T., Katano Y., Urano F., et al. Efficacy of ribavirin plus interferon-alpha in patients aged > or = 60 years with chronic hepatitis C. J Gastroenterol Hepatol 22 (2007) 989-995
30. Arase Y., Ikeda K., Suzuki F., et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 50 (2007) 16-23
31. Iacobellis A., Siciliano M., Perri F., et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 46 (2007) 206-212
32. Nevens F., Goubau P., Van Eyken P., et al. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 13 (1993) 15-19